Radiation Maculopathy Clinical Trial
Official title:
Study of Retinal and Vascular Features by Optical Coherence Tomography and Optical Coherence Tomography Angiography After Intravitreal Injections of Ranibizumab in Radiation Maculopathy
This study evaluates the retinal and vascular features in patients with radiation maculopathy under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography.
The radiation maculopathy is a consequence of radiotherapy for treatment of choroidal
melanoma. The radiation maculopathy is characterized by the compromission of the macular
microvasculature that can lead to the leakage, lipid exudates, hemorrhages, teleangiectasie,
macular edema, non perfusion areas with consequent significant impaiment of visual acuity.
Ranibizumab is a vascular endothelial growth factor antagonist and it represents an efficacy
treatment acting on vascular hyperpermeability. The optical coherence tomography and optical
coherence tomography angiography represent novel and non-invasive diagnostic techniques that
allow a detailed analysis of retinal and vascular features. The study evaluates the changes
in optical coherence tomography and optical coherence tomography angiography parameters at
baseline and after intravitreal injections of Ranibizumab at the last follow up to one year
in patients affected by radiation maculopathy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01471054 -
Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT00540930 -
Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy
|
Phase 4 |